Full Year 2022 Ucb SA Earnings Call Transcript
Welcome to the UCB Full Year 2022 Capital Market Call. My name is Antje here, and I'm heading Investor Relations at UCB. Before I introduce you to the agenda today and hand over to the speakers, I'd like to make two remarks. This video conference is being recorded. This presentation and the following Q&A session are covered by the disclaimer and safe harbor statement as stated on Slide two of the deck. Please kindly read this carefully. With this, I'd like to introduce you to our speakers today. We will start with our CEO, Jean-Christophe Tellier, followed by our Chief Medical Officer, Iris Loew-Friedrich and she will hand over to our Head of Neurology, Charl van Zyl, who will then turn it to the Head of Immunology, Emmanuel Caeymaex. And the conclusion will be done by our -- the financial conclusion will be done by our Chief Financial Officer, Sandrine Dufour. Jean-Christophe will then finally briefly conclude this presentation before we hand over to the Q&A session. For the Q&A session, please turn up your questions into the chat or if you
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |